Syndax Pharmaceuticals SNDX EPS (Basic)
EPS (Basic) at other companies
Other financials
Where this comes from
Reported directly by Syndax Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:EarningsPerShareBasic.
The official record: Syndax Pharmaceuticals’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Syndax Pharmaceuticals's eps (basic).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Syndax Pharmaceuticals's EPS (basic)?
- Syndax Pharmaceuticals (SNDX) reported EPS (basic) of -$0.48 in Q1 2026.
- How has Syndax Pharmaceuticals's EPS (basic) changed year-over-year?
- Syndax Pharmaceuticals's EPS (basic) increased by 51.0% year-over-year, from -$0.98 to -$0.48.
- What is the long-term trend for Syndax Pharmaceuticals's EPS (basic)?
- Over 3 years (2022 to 2025), Syndax Pharmaceuticals's EPS (basic) has grown at a 10.3% compound annual growth rate (CAGR), from -$2.45 to -$3.29.
- What does EPS (basic) mean?
- Net income available to common shareholders divided by the weighted-average number of common shares outstanding during the period. Does not account for dilutive securities.